|
**Overview**: CMR Atotech India Panel**Introduction**: The CMR Atotech India Panel is a diagnostic tool designed for comprehensive health screening using serum samples and radiology. In India, non-communicable diseases (NCDs) account for ~63 percent of deaths, with diabetes (~77 million adults), dyslipidemia, hypertension, and cardiovascular risks high in urban and increasingly rural populations. Routine screening is essential for early detection amid underdiagnosis in low-SES groups, limited preventive care access, and rising lifestyle diseases. Symptoms may be silent in early stages, but complications include heart disease, stroke, kidney failure. Per preventive medicine and biochemistry practices aligned with ICMR/NCD guidelines, the test employs spectrophotometry for biochemical markers over 1-2 days with high sensitivity/specificity, combined with radiology (chest X-ray, ECG) for basic assessment. This diagnostic falls under routine health check and targets adults for comprehensive screening, addressing early detection of metabolic and cardiorespiratory risks to guide lifestyle interventions or treatment. With high morbidity from underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing NCD burden. Its combined approach ensures reliable screening in India's diverse settings.**Other Names**: CMR Atotech Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/radiology, compliant with 2025 standards.**Historical Milestone**: Expanded as preventive packages; in India, promoted with NCD control programs.**Purpose**: The test screens for 5 parameters including fasting glucose to guide comprehensive health assessment, detect early NCD risks, inform interventions.**Test Parameters**: 1. Fasting Glucose, 2. Total Cholesterol, 3. Creatinine, 4. Chest X-Ray, 5. ECG.**Pretest Condition**: Fasting 10-12 hours required; patients should report any symptoms or family history of NCDs.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on lifestyle, family history of NCDs, symptoms, or previous screenings.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated NCDs including cardiovascular complications or diabetes progression, benefits of early detection, and minimal discomfort from blood draw/imaging.**Procedural Considerations**: The test involves sample processing using spectrophotometry and radiology by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days. Facilities must maintain controlled environments, adhere to quality assurance protocols, and follow safety guidelines for imaging.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage, hemolysis, or recent meals can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible NCD risks, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up in high-risk individuals.**Specialist Consultation**: General physicians or preventive medicine specialists should be consulted for interpretation, lifestyle counseling, and coordination with NCD programs.**Additional Supporting Tests**: Full lipid profile, HbA1c, or stress test for confirmation.**Test Limitations**: The test may miss early subclinical disease or require repeat screening; comprehensive approach with clinical correlation required.**References**: ICMR NCD Guidelines 2023, National Health Profile India 2024. |
